Company: CMND
Filing Date: 2025-12-10
Form Type: 6-K
Source: 0001213900-25-120091
Chunk: 0

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-10
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: December 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS</div>

Clearmind Medicine Inc. (the “Company”)
is announcing that it will effect a reverse share split of the Company’s common shares at the ratio of 1-for-40, such that each
forty (40) common shares, no par value, shall be consolidated into one (1) common share, no par value. The first date when the Company’s
common shares will begin trading on the Nasdaq Capital Market after implementation of the reverse split will be Monday, December 15, 2025.

Following the implementation of the reverse split,
the Company’s authorized share capital will remain unchanged. The reverse split will adjust the number of issued and outstanding
common shares of the Company from 59,991,852 common shares to 1,499,796 common shares (subject to any further adjustments based on the
treatment of fractional shares).

No fractional common shares will be issued as
a result of the reverse split. All fractional common shares will be rounded up to the nearest whole common share. In addition, a proportionate
adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding warrants
and options entitling the holders to purchase common shares. The new CUSIP number for the common shares will be 185053501.

On December 10, 2025, the Company issued a press
release titled “Clearmind Medicine Announces 1-for-40 Reverse Share Split.” A copy of the press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.

This Form 6-K, including the first four paragraphs
and the section